Peer Review History
| Original SubmissionNovember 6, 2020 |
|---|
|
PONE-D-20-34947 Strengthening government’s response to COVID-19 in Indonesia: a modified Delphi study of medical and health academics PLOS ONE Dear Dr. Mahendradhata, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by 25th June 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Rubeena Zakar, Ph.D Academic Editor PLOS ONE Additional Editor Comments: Please strictly follow authors' guidelines by the journal while revising your manuscript. Please find below reviewers' comments. Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please provide additional details regarding participant consent. In the ethics statement in the Methods and online submission information, please ensure that you have specified what type you obtained (for instance, written or verbal, and if verbal, how it was documented and witnessed). If your study included minors, state whether you obtained consent from parents or guardians. If the need for consent was waived by the ethics committee, please include this information. 3. In the Methods section, please describe in detail by what method the webinar discussion sessions were conducted. For instance, please provide information on the duration of the webinar, who conducted the webinar and their training experience and background, duration and finally how content was recorded and analysed. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: N/A ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: The authors aim to evaluate and provide further direction to Indonesia's Covid-19 response. To do so, they rely on a Delphi-style survey using the COVID-SCORE tool. Ultimately, this allows them to evaluate the government's response and identify key areas for improvement. This is clearly an important topic that merits consideration. Sadly, in the current form, I cannot recommend publication. I will not comment on individual aspects of the manuscript but rather I wish to focus on what I see as the two related major hindrances: the methodology and the discussion/recommendations. The methodology is very rigid and largely seems to be a the same questionnaire applied twice. Though there are optional short responses, there seems to be little room to obtain more in-depth observations and recommendations from the experts. An open-ended survey or focus group discussion with selected experts would be needed to do so. Though you mention having held a webinar, it is not clear if this helped build on the results in any way. This leads to the second major issue. The recommendations in the manuscript are vague and therefore of limited use. For example, you mention the importance of a testing strategy or contact tracing. Yet there is little specific insight or recommendations on how these items are being specifically implemented in Indonesia and how they can be improved. In other words, the manuscript merely emphasizes the importance of such items, but there is little country-specific information provided. Moving forward, more specific recommendations and context need to be provided. This can be done by sourcing additional local news/policy/literature as well as by conducting a third qualitative step in your Delphi study, whereby you validate and discuss the results in one or more focus groups with relevant experts. I feel such a step is needed to deepen the manuscript and maximize its relevance. Reviewer #2: The paper is important to inform the Indonesia government in tackling the COVID-19 pandemic. It is well written in very good English and understandable to read. The strength of this paper is the implementation of the COVID-19 assessment scorecard (COVID-SCORE) in a modified Delphi method. The results may be used to develop new models of preparedness and response for future public-health threads. To make it better, the authors may: • Line 156 � please clarify that the second cycle is the final results (no other returning the questionnaire to the researchers again) • Line 189 � it may be better if the majority comes first (68.5% doctoral degree vs 31.5% master degree) • Line 192-193 � how about the 17 participants who directly involved with COVID-19 response team? Why were they not excluded from the survey related to their possibility of subjectivity? • Line 207/ Table 1. There is a column of “Neither agree nor disagree” and the columns for assessment of comments consisting of positive, negative, or mixed comments. However, in the analysis, only ‘agreement’ or ‘disagreement’ are described. Also, there are no definitions for positive, negative, and mixed sentiment. • Line 468. After stating the Wuhan government failure in early communication, it will be more informative if there are any data about communication of Indonesia government in the early pandemic, such as the early response of the previous Minister of Health who was not able to build the public trusts. Also, the role of MoH spokesman should be discussed. • Line 487-488. The important of social media in communication � is there any data about the quality of government’s social media and how the government tackle the false pandemic information. There are also a few independent organizations that manage social media account to provide pandemic information and also to identify discrepancy data in COVID-19 daily report (e.g., @pandemictalks; @kawalcovid19) � it would be interesting to discuss their role in public health communication and how the government response. • Line 494-510 about enhancing testing and contact tracing � it would be useful if the authors update the impacts of latest diagnostic methods used in Indonesia (e.g., RDT antigen and Genose) as these methods have already been regulated by the government to trace and screen. • P 522-523, about app-based digital tracing � there is an interesting article to enrich the discussion: Gasser U, Ienca M, Scheibner J, Sleigh J, Vayena E. Digital tools against COVID-19: taxonomy, ethical challenges, and navigation aid. Lancet Digit Health. 2020 Aug;2(8):e425-e434. doi: 10.1016/S2589-7500(20)30137-0. Epub 2020 Jun 29. PMID: 32835200; PMCID: PMC7324107. • Related to app-based digital tracing, kindly update the Indonesian government-sponsored tracing app, PeduliLindungi. PeduliLindungi is an android-based mobile application developed by the Indonesian government to mitigate the spread of COVID-19. The application relies on the willingness of people to share their current health condition and make it available for tracking using global positioning system (GPS) and Bluetooth technology. • In the analysis section, the authors mentioned the webinar between experts and the National Planning Development Agency to discuss findings of the study� it would be nice if authors discuss the responses from the National Planning Development Agency during the webinar and provide the outcomes of the meeting. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Louis Moustakas Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-20-34947R1Strengthening government’s response to COVID-19 in Indonesia: a modified Delphi study of medical and health academicsPLOS ONE Dear Dr. Mahendradhata, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by 30th October 2021. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Rubeena Zakar, Ph.D Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: (No Response) Reviewer #3: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: Thank you for addressing my issues. I would like to congratulate you on the improvement in your paper. I only have one issue left regarding the GeNose C19 since there was updating news. You added: “More recently, the government has also adopted GeNose C19, a breath-based COVID-19 detection device developed by Indonesian scientists. Initial trial on the device revealed 89-92% sensitivity for detecting positive cases, comparable to RT-PCR (89%) and antigen-based rapid test (89.9%) [34]. The tool that detects the infection through exhaled volatile organic compounds gives results in only three minutes. It costs only US$ 0.7-1.7 or around 11-140 times cheaper than the other two tests. [34] The Ministry of Transportation has deployed the tool in train stations and bus terminals, hoping that the device can speed up the passengers screening process." As we know that the GeNose C19 is now halted by the Government upon its controversy. I would like you to delete the discussion about the GeNose C19 to avoid the confusion. Kindly highlight the effort from the Government in providing effective and reliable COVID-19 screening modalities, and also how the Government take the expert and epidemiologist recommendation. Thank you. Reviewer #3: Research Summary and overall impression The study assessed the response efforts by the Indonesian government to the COVID-19 pandemic from the time of first outbreak in February, 2020 in Indonesia. This work involved medical and health academics from ten universities across Indonesia, whose views on 20 prepared statements were captured using a five-point Likert scale in a modified Delphi study. Suggested areas requiring improvement were also put forth by participants. Overall, this was a good study, which has been well-presented. This is a relevant study as far as COVID-19-related Public Health issues are concerned. Some insight is provided the reader into the strengths and shortfalls of the Indonesian government in its handling of the COVID-19 outbreak in the archipelagos – issues which are common to many countries across the globe, developed and developing alike. There however are a few observations which the authors should note: Major Issues 1. Line 369: (majority agreement, 51.4% disagree) – this is a rather confusing presentation. Although one deduces from reading further that the first agreement is actually degree of consensus, and the second agreement with percentage indicates the kind of agreement (whether agreed or disagreed), it could adversely impact the smooth reading and flow of the manuscript. I would suggest that different categorizations (such as ‘poor consensus’, ‘consensus’, ‘good consensus’ and ‘strong consensus’) could be adopted instead of what is currently being used (i.e. ‘no consensus’, ‘majority agreement’, ‘consensus’, and ‘strong consensus’). This could also greatly improve understanding at first read. Same issue applies to Table 1 as well 2. Table 1: I’m not so sure what the relevance of the p-value column is in this work. No mention is made of it in either the results or the discussion sections. Meanwhile, this could serve to justify why it was needful to conduct the study twice with the same participants. I think it would enrich the manuscript if they could insert such information Minor Issues 1. Lines 439 – 440: I think the authors should be more careful with their tenses. It would be helpful if they could go through the entire manuscript to correct these issues. 2. Lines 389 – 392: Unclear statement. Please revise. 3. Lines 518 - 519: The clause ‘through social media and employ strategies for improved communication management to citizens through social media…’ was repeated. Please revise. Other/General remarks: I think the study was well-done and well-presented. However, attention must be paid to modify the categorizations; as well as correct tenses and other minor grammatical errors. This would greatly enhance the readability of the study. I would recommend it for publication. Thank you. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
| Revision 2 |
|
PONE-D-20-34947R2Strengthening government’s response to COVID-19 in Indonesia: a modified Delphi study of medical and health academicsPLOS ONE Dear Dr. Mahendradhata, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by 24 February 2022. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Rubeena Zakar, Ph.D Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #3: All comments have been addressed Reviewer #4: All comments have been addressed Reviewer #5: (No Response) Reviewer #6: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: Partly Reviewer #6: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: No Reviewer #6: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: Yes Reviewer #6: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: Yes Reviewer #6: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #3: Overall Impressions: All major issues have been catered for by the co-authors. There are however a number of minor issues, mainly typographical and grammatical, that the co-authors would need to address: Issues: Location Issue Line 19 ‘government’s’ was repeated twice Line 19 Remove ‘the’ in ‘…government’s handling of the COVID-19…’ Line 25 Remove ‘have’ in the statement: ‘All participants who have completed…’ Line 27 ‘rank’ should be ‘ranked’ Replace ‘priority with ‘list’ Line 31 Replace ‘strengthen’ with ‘strengthening’ Line 33 Replace ‘ensure’ with ‘ensuring’ Line 35 Replace ‘boost’ with ‘boosting’ Line 36 Replace ‘facilitate’ with ‘facilitating’ Line 122 Replace ‘has’ with ‘had’ Line 132 Replace ‘university’ with ‘respective universities’ Line 176 Replace ‘will be’ with ‘was’ Line 177 Replace ‘will be’ with ‘was considered’ Line 188 Replace ‘can’ with ‘could’ Line 190 Replace ‘are’ with ‘were’ Line 225 Replace ‘has’ with ‘have’ Line 289 Capitalize ‘low’ Lines 290, 292, 298, 300, 301, 302, 304, 305 Replace ‘,’ with ‘;’ Line 300 Replace ‘communicate’ with ‘communicated’ Line 301 Replace ‘have’ with ‘has’ Line 303 Replace ‘has’ with ‘have’ Line 310 Replace ‘eight’ with ‘eighth’ Line 337 Modify ‘at what extent does’ to ‘the extent to which’ Line 359 Replace ‘needs’ with ‘needed’ Line 394 Replace ‘suggest’ with ‘suggested that’ Line 396 Modify ‘rural’ to read ‘rural areas’ Line 410 Replace ‘issue’ with ‘issues’ Line 417 Modify ‘price skyrocketing’ to read ‘prices were skyrocketing’ Line 446 Replace ‘philanthropic’ with ‘philanthropies’ Line 504 Replace ‘contradict’ with ‘contradicted Line 531 Replace ‘dan’ with ‘and’ Reviewer #4: Line 15: Please make sure to use one common tense (either present or past) throughout the abstract. There are multiple grammatical mistakes in this paragraph. Please correct them. Line: 19: Please omit the repeated words. Line 23: Please clarify how many rounds of data collection was performed. Line 46: Please be consistent when characterizing the COVID-19 as a pandemic. Here the authors have depicted it as an epidemic, which may confuse the readers. Line 60: Please explain the term "zero case" - is it an academic term? If so, please provide a reference for it - otherwise please explain clearly for the readers. Line 62: Should it be specific quarantines, or specific policies/instructions/guidelines for quarantines? Please clarify. Line 64: Is there any data regarding Indonesian nationals versus tourists arriving in the country during that period of time? Please provide references as Indonesia is a known tourist country. Line 67: Please provide information on the first COVID-19 related death occurring in Indonesia - when did it occur and how did that impact the governments' decisions? Line 75: When the authors mention "Indonesia's vulnerable health system" - what do they mean? Please provide some context as to why the healthcare system is vulnerable in Indonesia. Line 76: Please clarify what the non-COVID-19 related impacts are. Line 78: Please be consistent with WHO announcements on COVID-19 being a pandemic. Line 82: Please clarify the difference between health professionals (line 80) and health academics (line 82). Please use one term consistently throughout the paper. Line 91: A better term that can be used here is "to achieve the study objectives". Line 96: Please correct for double spaces throughout the manuscript. Please use single spaces. Line 102: If possible, please provide references of other studies that have used a similar methodology to study the COVID-19 pandemic. Line 104: Please clarify what the "modified Delphi study" is. Is this different from the original method? If so, how and why is it different? Please clarify for the readers. Line 114: Please provide some context as to what type of "adopted statements" were utilized in the study. Are these statements from the Indonesian government? If so, which government body issued them and in what context? Was there a specific time frame from which the statements were collected? What was the inclusion criteria for these statements? Please clarify. Line 126: Why is regional representation important in this context? Please clarify. Line 127: When describing the sampling technique, please use more academic/formal terms such as purposive sampling etc. Line 132: Did the authors follow a snowball sampling technique in the second stage of sampling? Please clarify the different stages that were used during the sampling process. Line 134: Was the data collection process completed online? Please clarify this at the beginning of the methods section. Otherwise, it is confusing to the reader. Line 137: How was this number (about 30) determined? Please clarify. Line 148: Please clarify why 2 languages were used in the survey instrument. Line 159: Why was not the data de-identified? Why did the researcher have access to the identity of the survey participants? Please clarify. Line 163: Please clarify - was the feedback shared with the participants? Line 167: Please correct the spelling for calculated. Line 170: Please clarify how this decision criteria was determined. Please provide relevant references if possible. Line 180: Please clarify what is meant by 1,5 hours. Line 181: In case a respondent disagreed with the results - how was that handled by the researchers? What implications might it have for the results of the study? Line 189: Earlier it was mentioned that the researchers/authors had access to participant identities. This could have affected the responses from the participants. How was this handled by the authors? Line 287: Was this a recommendation made by the respondents? Line 325: This can be better expressed as quality of product. Line 337: Please correct grammatical issues with this sentence. Line 344: Please provide a reference for this guideline. Line 355: Please rewrite this sentence to make it clear for the readers. Line 376: Please provide references for these resources. Line 410: Please correct grammatical issues with this sentence. Line 446: Please correct grammatical issues with this sentence. Line 451: Are these 2 separate departments of the government? Please clarify. Line 470: Overall, the discussion section should be made more concise, as several paragraphs can be summarized into smaller ones. Line 471: The results mentioned here has already been mentioned in the results section. This paragraph is thus no longer needed. Line 478: The results mentioned here has already been mentioned in the results section. This paragraph is thus no longer needed. Line 513: Please summarize the discussion on communication in a more concise way. Line 612: Please clarify the meaning of higher levels of evidence. Reviewer #5: Thanks for the authors for introducing us how medical and health academics view the Indonesian government's handling of the COVID-19 and which areas of health systems need to be prioritized. However, there are several concerns: 1. Although the author explains the reasons for using the Delphi method in page 5 lines 93-95, this kind of research does not require the Delphi method (time-consuming and laborious). The same result would have been obtained if a questionnaire had been used. The commonly used Delphi method is only used to forecast, put forward the index system and determine the specific index. 2. In the research design section, the COVID-19 assessment scorecard consists of 19 policy statements [1], but the author noted 20 in the manuscript. 3. It is odd for the authors to use the Cambridge Dictionary's definition of scholarship to select a study population. The views of the health sector and healthcare providers on policies to control COVID-19 are even more important. The study was underrepresented. 4. In the results section, it is more intuitive to use the expert status table. For example, age can be expressed in three groups. 5. Please explain in the methods section why the P value is calculated. In general, the Delphi method does not require the calculation of P- values. 6. It is too tedious to present all policy statements in the results. Simplify them. 7. From the results of this study, moderate consensus was reached on only 5 statements, low consensus was reached on 13 statements, and no consensus was reached on 2 statements. In the Delphi method, the reliability of the results should be proved. However, the expert' authority coefficient (Cr) and the coefficient of variation (CV) are necessary. The reliability and representativeness of the manuscript are worrisome. [1] Lazarus JV, Binagwaho A, El-Mohandes AAE, Fielding JE, Larson HJ, Plasència A, et al. Keeping governments accountable: the COVID-19 Assessment Scorecard (COVID- SCORE). Nat Med. 2020 Jul;26(7):1005-1008. Reviewer #6: The authors present an important application of expert elicitation to guide policy decision making in the context of COVID-19. The methods for the expert elicitation are clearly reported, and the results are presented in a well-organized manner. The authors have responded satisfactorily to the comments from both rounds of reviewers. I have a couple of minor comments. First, pg 15, please specify in text that no statements received a high consensus level. Second, line 318, the statement “the government should involve domestic private manufacturers” is phrased differently from all other scorecard descriptions which state whether the experts think the government has done the task. Could the authors please clarify if this should in fact be past tense (has) or if future tense (should) is correct. If the latter, then please clarify why the interpretation for this statement is different. Finally, I saw no mentions to the supplemental materials made in text. Please add references to these materials in the requisite sections. Additionally, the code book submitted in appendix 3 appears to be incomplete with descriptions absent and titles that do not correspond to the data elements in the data file. Have the authors considered attaching the complete survey as an additional supplement? ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #3: No Reviewer #4: Yes: Redwan Bin Abdul Baten Reviewer #5: No Reviewer #6: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
| Revision 3 |
|
Strengthening government’s response to COVID-19 in Indonesia: a modified Delphi study of medical and health academics PONE-D-20-34947R3 Dear Dr. Mahendradhata, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. You also need to correct the grammatical errors in your manuscript. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Rubeena Zakar, Ph.D Section Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #3: All comments have been addressed Reviewer #4: All comments have been addressed Reviewer #5: (No Response) Reviewer #6: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: Partly Reviewer #6: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: No Reviewer #6: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: No Reviewer #6: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #3: Yes Reviewer #4: Yes Reviewer #5: No Reviewer #6: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #3: Overall Impressions: I think this is a highly-improved version of the earlier drafts. I would like to commend the co-authors for being patient to incorporate the suggested modifications. I still have very minor suggestions – mainly grammar. Location Issue Line 17 Replace ‘continued’ with ‘continue’ Line 73 Replace ‘By’ with ‘As at’ Line 81 Replace ‘need’ with ‘needs’ I am for the publication of this manuscript. Thanks. Reviewer #4: Thanks to the authors for addressing the comments/suggestions from all reviewers. The revisions have certainly improved the quality of the manuscript. Reviewer #5: The author does not understand the relevant knowledge and writing method of Delphi method. Most of the questions I raised were evaded. This is not the status of a scientific worker. Therefore, I do not think this manuscript qualifies for publication in Plos One. From the results of this study, moderate consensus was reached on only 5 statements, low consensus was reached on 13 statements, and no consensus was reached on 2 statements. The results are worrying. In addition, it is odd for the authors to use the Cambridge Dictionary's definition of scholarship to select a study population. The views of the health sector and healthcare providers on policies to control COVID-19 are even more important. The study was underrepresented. So I have to reject it. Reviewer #6: The authors have addressed all comments raised by the reviewers. I have a few minor grammatical suggestions. Line 18: the word "the" was erronously deleted Line 34: should read "COVID-19 testing" Line 44: The authors may want to consider updating the number of COVID cases and deaths Line 82: should read "the government needs" and the authors may wish to provide additional context as to why this is needed Line 85 should read "First, to investigate" Line 86-87: should read "Second, to identify" Line 123: should read "academics who were not working in the institutions" line 270: should read "tracing" Line 272: shoudl read "the government had tried to address the health and" Line 279: should read "there were no sanctions" Line 289: should read "when people got tested" Line 322: should read "the government had tried" Line 345: should read "it ranked tenth" Line 480: should read "Only one-third" Line 505: should read "comunication was considered critical" Line 509: the '' before Wuhan should be delete Line 515: pandemic should not be capitalized Line 120: delete "and periodically" Line 537: should read "thus needs to improve" Pg 30: the authors may wish to update the values from August 2021 ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #3: No Reviewer #4: No Reviewer #5: No Reviewer #6: No ********** |
| Formally Accepted |
|
PONE-D-20-34947R3 Strengthening government’s response to COVID-19 in Indonesia: a modified Delphi study of medical and health academics Dear Dr. Mahendradhata: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Rubeena Zakar Section Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .